BioTime: Signed BAT2406 licensing and commercialization agreement with SteinCares, amount up to $10 million.

Baiothai announcement, the company signed an authorization, license, production, supply, and commercialization agreement with SteinCares, granting exclusive commercialization rights to BAT2406 injection in Brazil and other Latin American markets. The total amount of the agreement is up to 10 million US dollars, including a 1 million US dollar down payment and cumulative milestone payments not exceeding 9 million US dollars. At the same time, Baiothai will receive a revenue share in double-digit percentages based on the net sales as agreed in the contract. The agreement will be effective upon signing by both parties, with an initial term of fifteen years. The signing of the agreement is expected to have a positive impact on the company's future performance.